<DOC>
	<DOCNO>NCT00872521</DOCNO>
	<brief_summary>The purpose study determine efficacy treatment bortezomib ( combination doxorubicin dexamethasone ) previously untreated patient Multiple Myeloma .</brief_summary>
	<brief_title>A Study Efficacy Treatment With Bortezomib ( Combination With Doxorubicin Dexamethasone ) Previously Untreated Patients With Multiple Myeloma</brief_title>
	<detailed_description>This open-label , single-arm , multicentre study enroll approximately 105 patient . Open-label mean people involve study know identity intervention . Single-arm mean one group patient , receive treatment . Four 21-day cycle combination bortezomib i.v . ( intravenous ) 1.3 mg/m2 ( Days 1 , 4 , 8 11 ) , doxorubicin i.v . 20 mg/m2 ( day 1 4 ) dexamethasone p.o . ( mouth ) ( day 1 , 2 , 4 , 5 , 8 , 9 , 11 12 ) ( PAD ) give . Patients discontinued disease progress , unacceptable treatment-related toxicity occur . Following PAD treatment , patient peripheral blood stem cell ( PBSC ) collect , autologous stem cell transplant ( ASCT ) perform . Patients make monthly visit Study Doctor 1 year start treatment , attend final follow-up visit 2 year . Efficacy assessment response PAD make use International Myeloma Working Group ( IMWG ) criterion . The primary outcome compare overall response rate follow 4 cycle PAD induction therapy patient without extra copy long arm first chromosome ( 1q21 ) measure fluorescent situ hybridisation ( FISH ) marrow baseline . Patient report outcome assess use AQoL ( Assessment Quality Life ) . Safety evaluate throughout study assessment adverse event include change physical examination , concomitant medication , ECOG ( Eastern Cooperative Oncology Group ) score , vital sign clinical laboratory finding . A sample size 105 provide 80 % power ( a=0.05 ) detect difference overall response rate 28 % end 4 cycle PAD . This base assumption 44 % patient amplification 1q21 1 , 2 , overall response rate PAD combination therapy 80 % ; overall response rate PAD PAD therapy overcome 1q21 amplification assume 64 % , without 1q21 amplification assume 92 % . That : Overall Response Rate ( ORR ) = P1q21 amplify x ORRamplified + P1q21 amplify x ORRnot amplify i.e . 80 % = 44 % x 64 % + 56 % x 92 % . The sample size 105 allow 20 % drop-out rate . Four 21-day cycle PAD : combination bortezomib i.v . ( intravenous ) 1.3 mg/m2 ( Days 1 , 4 , 8 11 ) , doxorubicin i.v . 20 mg/m2 ( day 1 4 ) dexamethasone p.o . ( mouth ) ( day 1 , 2 , 4 , 5 , 8 , 9 , 11 12 ) .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Previously diagnose multiple myeloma eligible autologous stem cell transplantation meet pretreatment lab criterion ( define within protocol ) . Previously receive treatment multiple myeloma ( include prior therapy radiation pulse dexamethasone ) , except localise radiation solitary lesion plasmacytomas 4 day corticosteroid therapy current diagnosis smolder multiple myeloma , monoclonal gammopathy undetermined significance ( MGUS ) , Waldenstr√∂m Macroglobulinemia history malignancy within 5 year enrolment significant comorbidities .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>Multiple Myeloma</keyword>
	<keyword>transplant eligible</keyword>
	<keyword>doxorubicin</keyword>
	<keyword>dexamethasone</keyword>
	<keyword>bortezomib</keyword>
	<keyword>bortezomib resistance</keyword>
	<keyword>PAD induction</keyword>
	<keyword>PIMMS Trial</keyword>
</DOC>